Treatment for HIV, Prevention

Phase-Based Progress Estimates
3
Effectiveness
3
Safety
Vivent Health, Denver, CO
HIV, Prevention
Eligibility
18+
Male
What conditions do you have?
Select

Study Summary

To evaluate if utilizing Telehealth medicine for access to HIV PrEP will engage more Black and Latino Men who have sex with Men (MSM)

Treatment Effectiveness

Effectiveness Progress

3 of 3
This is further along than 93% of similar trials

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: 18 months

18 months
: To increase the number and proportion of individuals who start PrEP who have been under-represented in PrEP uptake including those who identify as Black and/or Latino MSM.
To assess the acceptability and implementation of the intervention by both patients and clinic staff.
To increase the number and proportion of individuals who are still taking PrEP and engaged in care at the end of 6 months by 30% and remain HIV negative including those who identify as Black and/or Latino MSM.

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Trial Design

0 Treatment Group

150 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · Phase 4

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 18 months

Trial Background

Cindy Firnhaber, Principal Investigator
Principal Investigator
Vivent Health
Closest Location: Vivent Health · Denver, CO
Photo of Denver  1Photo of Denver  2Photo of Denver  3
N/AFirst Recorded Clinical Trial
1 TrialsResearching HIV, Prevention
0 CompletedClinical Trials

Eligibility Criteria

Age 18+ · Male Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are able to understand and sign consent in English or with other language interpreter.
You are able to stay in the state catchment area of the license health care provider.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.